In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $520.00. Discover outperforming stocks and invest ...
In the latest market close, Vertex Pharmaceuticals (VRTX) reached $409.56, with a -0.62% movement compared to the previous day. This change was narrower than the S&P 500's 1.54% loss on the day.
If approved, it would give Vertex Pharmaceuticals a significant new revenue source beyond cystic fibrosis, especially as income from Casgevy remains low in the near term, helping to diversify its ...
Ratings for Vertex Pharmaceuticals VRTX were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...
Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...
Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...
VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX ...
ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth quarter 2024 ...